文献速递头颈与中枢神经肿瘤

重新审视头颈癌术后放化疗:RTOG 9501/EORTC 22931 长期更新联合分析

Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931.
PubMed 文献 · Ann Oncol · 2025-07-16

该研究联合分析 RTOG 9501 与 EORTC 22931 两项随机试验的 744 例术后头颈癌患者,中位随访 6.9 年。结果显示术后放化疗(CRT)较单纯放疗改善总生存(HR 0.81,95%CI 0.68-0.97,P=0.026),且交互检验未证实结外侵犯(ENE)和/或切缘阳性是预测标志物;CRT 降低肿瘤特异性死亡但增加其他原因死亡。

要点

  • 术后 CRT 较 RT 改善总生存,HR 0.81(95%CI 0.68-0.97,P=0.026)。
  • ENE 和/或切缘阳性交互检验 P=0.17,未证实其为预测标志物。
  • CRT 降低肿瘤特异性死亡(HR 0.68)但增加其他原因死亡(HR 1.51)。

核心结论

  • 在 EORTC 22931 与 RTOG 9501 联合人群中,术后放疗期间同步化疗改善头颈癌患者总生存。
  • ENE 和/或切缘阳性不是预测标志物,无这些特征的患者仍可能从 CRT 获益。
  • CRT 改善肿瘤特异性死亡,但部分被更高的其他原因死亡所抵消。
  • 作者认为,结合肿瘤学与患者相关因素细化最可能从术后 CRT 获益的人群,需要进一步探索。

研究设计与样本

  • 联合分析 RTOG 9501 与 EORTC 22931 两项随机试验中比较术后 CRT 与 RT 的 744 例患者。
  • 总生存采用 Cox 回归分析;肿瘤特异性死亡、其他原因死亡及复发结局采用竞争风险方法分析。
  • 采用交互检验评估 CRT 在不同亚组中的差异获益。

主要发现

  • 中位随访 6.9 年;全部患者中 CRT 改善总生存(HR 0.81,95%CI 0.68-0.97,P=0.026)。
  • ENE 和/或切缘阳性亚组 CRT 改善总生存(HR 0.71,95%CI 0.57-0.89,P=0.003),无这些特征亚组未改善(HR 0.94,95%CI 0.68-1.30,P=0.7),但交互检验无差异证据(P-interaction=0.17)。
  • 分析其他结局或单独评估 ENE 与切缘状态时,亦无交互证据。
  • CRT 显著降低肿瘤特异性死亡(HR 0.68,95%CI 0.55-0.83,P<0.001),但显著增加其他原因死亡(HR 1.51,95%CI 1.07-2.12,P=0.018)。
  • 术后 CRT 改善局部区域复发(HR 0.64,95%CI 0.48-0.85,P=0.002),但未改善远处转移(HR 0.83,95%CI 0.64-1.08,P=0.17)。

关键数值与推荐

  • 总生存:全部患者 CRT vs RT HR 0.81(95%CI 0.68-0.97,P=0.026)。
  • 总生存:ENE 和/或切缘阳性亚组 HR 0.71(95%CI 0.57-0.89,P=0.003);无这些特征亚组 HR 0.94(95%CI 0.68-1.30,P=0.7);交互 P=0.17。
  • 肿瘤特异性死亡 HR 0.68(95%CI 0.55-0.83,P<0.001);其他原因死亡 HR 1.51(95%CI 1.07-2.12,P=0.018)。
  • 局部区域复发 HR 0.64(95%CI 0.48-0.85,P=0.002);远处转移 HR 0.83(95%CI 0.64-1.08,P=0.17)。

临床怎么用

  • 术后放疗期间同步化疗可改善头颈癌患者总生存。
  • ENE 和/或切缘阳性不是选择术后 CRT 的预测标志物,无这些特征的患者仍可能获益。
  • 作者认为,结合肿瘤学与患者相关因素细化最可能从术后 CRT 获益的人群,需要进一步探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-operative chemoradiation (CRT) is generally recommended for head and neck cancer patients with extranodal extension (ENE) and/or positive margins, but not for patients without these features, based on a post hoc analysis of Radiation Therapy Oncology Group (RTOG) 9501 and European Organisation for Research and Treatment of Cancer (EORTC) 22931. However, this analysis lacked tests of interaction necessary to identify a predictive biomarker. In addition, updated data are now available. PATIENTS AND METHODS: This study assessed 744 patients enrolled on RTOG 9501 and EORTC 22931, randomized trials that compared CRT with radiation (RT) following surgery. Overall survival (OS) was analyzed with Cox regression. Cancer-specific mortality (CSM), other-cause mortality (OCM), and recurrence outcomes were analyzed with competing risks methodology. Tests of interaction assessed for differential benefits of CRT in various subgroups. RESULTS: Median follow-up was 6.9 years. Among all patients, CRT improved OS [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.68-0.97, P = 0.026]. Although CRT improved OS in the subgroup with ENE and/or positive margins (HR 0.71, 95% CI 0.57-0.89, P = 0.003) and not in those without these features (HR 0.94, 95% CI 0.68-1.30, P = 0.7), tests of interaction showed no evidence of a differential effect of CRT in these subgroups (P-interaction = 0.17). There was also no evidence of interaction when analyzing other outcomes, or when assessing ENE and margin status individually. While CRT significantly reduced CSM (HR 0.68, 95% CI 0.55-0.83, P < 0.001), it also significantly increased OCM (HR 1.51, 95% CI 1.07-2.12, P = 0.018). Post-operative CRT improved locoregional recurrence (HR 0.64, 95% CI 0.48-0.85, P = 0.002), but not distant metastasis (HR 0.83, 95% CI 0.64-1.08, P = 0.17). CONCLUSIONS: Concurrent chemotherapy improved OS in head and neck cancer patients undergoing post-operative radiotherapy in the combined populations of EORTC 22931 and RTOG 9501. ENE and/or positive margins are not predictive biomarkers, and patients without these features may still benefit from CRT. CRT improved CSM, but this was partly offset by higher OCM. Refining the population most likely to benefit from post-operative CRT, taking into consideration both oncologic and patient-related factors, needs further exploration.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Zumsteg ZS, Luu M, Fortpied C, et al. Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931. Ann Oncol. 2025. PMID: 40680992. doi:10.1016/j.annonc.2025.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。